A Phase II Trial of Sequential MTx and 5-FU Alternated with 4-Epidoxorubicin and Cisplatin in Advanced Gastric Cancer

Abstract

Twenty-one patients with advanced gastric adenocarcinoma were treated with a combination chemotherapy schedule of sequential methotrexate and 5-fluorouracil alternated with 4-epidoxorubicin and cisplatin. This scheme was active, with 7 partial responses leading to a response rate of 33% (± 20%). In two cases the tumor became operable. No severe toxicity developed and the treatment was usually well tolerated.